Table 2.
No Effect of Pimecrolimus Treatment on Delayed-Type Hypersensitivity. In a 1 Year Study, Response to Recall Antigens Was Not Significantly Different Between Control and Pimecrolimus-Treated Patients*
| Skin Antigen | Pimecrolimus n = 82 (%) | Control n = 30 (%) | P Value† |
|---|---|---|---|
| Tetanus | 63.4 | 60.0 | .826 |
| Diphtheria | 42.7 | 23.3 | .079 |
| Streptococcus | 7.3 | 0.0 | .190 |
| Tuberculin | 17.1 | 13.3 | .776 |
| Candida | 13.4 | 3.3 | .176 |
| Trichophyton | 8.5 | 10.0 | .726 |
| Proteus | 18.3 | 6.7 | .151 |
| Negative control | 3.7 | 0.0 | .563 |
| 1 positive antigen | 73.0 | 67.0 | .820 |
*
Reprinted with permission from Pediatrics.[27] Copyright 2002, American Academy of Pediatrics
†
P value from time to first occurrence analysis (log-rank test)